MX2020014154A - Anticuerpo neutralizante zika y composiciones y metodos para usarlo. - Google Patents
Anticuerpo neutralizante zika y composiciones y metodos para usarlo.Info
- Publication number
- MX2020014154A MX2020014154A MX2020014154A MX2020014154A MX2020014154A MX 2020014154 A MX2020014154 A MX 2020014154A MX 2020014154 A MX2020014154 A MX 2020014154A MX 2020014154 A MX2020014154 A MX 2020014154A MX 2020014154 A MX2020014154 A MX 2020014154A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- zika virus
- reducing
- risk
- preventing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 10
- 208000020329 Zika virus infectious disease Diseases 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 5
- 208000035332 Zika virus disease Diseases 0.000 abstract 5
- 241000907316 Zika virus Species 0.000 abstract 3
- 210000003754 fetus Anatomy 0.000 abstract 2
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000000521 hyperimmunizing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 208000004141 microcephaly Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se refiere a las composiciones, incluidas las composiciones hiperinmunes, que comprenden los anticuerpos neutralizantes del virus Zika y los métodos para usarlos. Por ejemplo, métodos para tratar, prevenir o reducir el riesgo de infección por el virus Zika; métodos para reducir la carga viral de un virus Zika; métodos para provocar una respuesta inmunológica contra un virus Zika; métodos para prevenir o reducir el riesgo de transmisión de una infección por el virus Zika de un sujeto; métodos para tratar, prevenir o reducir el riesgo de una infección por el virus Zika en un embrión o un feto; métodos para aumentar el título de anticuerpos contra una infección por el virus Zika; y métodos de inmunización pasiva contra una infección por el virus Zika, y métodos para prevenir o reducir la gravedad o el riesgo de microcefalia en un feto.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688330P | 2018-06-21 | 2018-06-21 | |
| US201862722647P | 2018-08-24 | 2018-08-24 | |
| US201862723558P | 2018-08-28 | 2018-08-28 | |
| US201862740479P | 2018-10-03 | 2018-10-03 | |
| PCT/IB2019/055275 WO2019244130A1 (en) | 2018-06-21 | 2019-06-21 | Zika neutralizing antibody compositions and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020014154A true MX2020014154A (es) | 2021-05-12 |
Family
ID=68983511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020014154A MX2020014154A (es) | 2018-06-21 | 2019-06-21 | Anticuerpo neutralizante zika y composiciones y metodos para usarlo. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210147514A1 (es) |
| EP (1) | EP3810198A4 (es) |
| AU (1) | AU2019291659A1 (es) |
| BR (1) | BR112020026000A2 (es) |
| CA (1) | CA3104603A1 (es) |
| MX (1) | MX2020014154A (es) |
| WO (1) | WO2019244130A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107906B1 (en) * | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| IL261536B (en) * | 2016-03-03 | 2022-07-01 | Kamada Ltd | Treatment and prevention of infectious diseases caused by the Zika virus |
| US20190233505A1 (en) * | 2016-09-06 | 2019-08-01 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
-
2019
- 2019-06-21 WO PCT/IB2019/055275 patent/WO2019244130A1/en unknown
- 2019-06-21 CA CA3104603A patent/CA3104603A1/en active Pending
- 2019-06-21 US US17/254,479 patent/US20210147514A1/en not_active Abandoned
- 2019-06-21 MX MX2020014154A patent/MX2020014154A/es unknown
- 2019-06-21 BR BR112020026000-2A patent/BR112020026000A2/pt not_active IP Right Cessation
- 2019-06-21 EP EP19821551.9A patent/EP3810198A4/en not_active Withdrawn
- 2019-06-21 AU AU2019291659A patent/AU2019291659A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020026000A2 (pt) | 2021-03-23 |
| WO2019244130A1 (en) | 2019-12-26 |
| EP3810198A4 (en) | 2022-03-30 |
| CA3104603A1 (en) | 2019-12-26 |
| US20210147514A1 (en) | 2021-05-20 |
| EP3810198A1 (en) | 2021-04-28 |
| AU2019291659A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| MX2021015687A (es) | Anticuerpos humanos contra glicoproteina del virus ebola. | |
| MX2020007888A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| JOP20200091A1 (ar) | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري | |
| EA201391713A1 (ru) | Нейтрализующие вирус иммунодефицита человека антитела и способы их применения | |
| WO2017164678A3 (ko) | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 | |
| PH12015502164A1 (en) | Flavivirus neutralizing antibodies and methods of use thereof | |
| PH12020550025A1 (en) | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof | |
| WO2017044895A3 (en) | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF | |
| BR112018010679A8 (pt) | métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina | |
| AU2018388102A1 (en) | Cross-immunizing antigen vaccine and method for preparation thereof | |
| MX2020014154A (es) | Anticuerpo neutralizante zika y composiciones y metodos para usarlo. | |
| MX2023005654A (es) | Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| WO2017053525A3 (en) | Influenza vaccine and therapy | |
| WO2012058492A3 (en) | Viral vaccine and process for preparing the same | |
| SG11202010531SA (en) | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination | |
| PL428045A1 (pl) | Szczepionka do profilaktyki i leczenia zakażeń C. difficile oraz jej zastosowanie | |
| BR132018069012E2 (pt) | uso de anticorpos policlonais humanos ou fragmentos destes, e, composição farmacêutica | |
| PH12021550987A1 (en) | Anti-rabies monoclonal antibodies and cocktail thereof | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| WO2022178216A3 (en) | Corona virus antigens and epitopes and proteins that bind thereto | |
| WO2021007070A3 (en) | Chimeric antigens for treating viral infection | |
| EA201891048A1 (ru) | Антитело, нейтрализующее респираторно-синцитиальный вирус человека |